| Previous Close | 73.42 |
| Open | 73.32 |
| Bid | 73.32 x 600 |
| Ask | 74.48 x 100 |
| Day's Range | 73.28 - 74.41 |
| 52 Week Range | 63.76 - 88.85 |
| Volume | 8,874,021 |
| Avg. Volume | 8,651,084 |
| Market Cap | 96.38B |
| Beta | 0.96 |
| PE Ratio (TTM) | 7.80 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 2.08 (2.82%) |
| Ex-Dividend Date | 2017-06-14 |
| 1y Target Est | N/A |
- Reuters•2 hours ago
HIV fight advances with new drug cocktails, fresh vaccine hopes
Three decades after approval of the first-ever AIDS treatment, HIV medicine is seeing a new wave of innovation with scientists reporting positive data on Monday for improved drug cocktails and a novel experimental vaccine. The Achilles heel for us is drug resistance because the virus is incredibly quick to mutate," Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Centre in South Africa, said. The race for better and more convenient medicines has made HIV a rich battleground for drug companies such as Gilead Sciences and GlaxoSmithKline, which generate billions of dollars from modern therapies.
- TheStreet.com•16 hours ago
The Worm Has Turned in Biotech's Favor
But this needs to heat up again for the sector to rally in a big way.
